Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We can only predict. We are not part of management.
I would rather predict and show my support of the company while
slam
And keep slamming.
It looks to me that the investors that remain are here till the end
But I’m not giving you a nickel.
Watch your prediction too…
Fantastic!!
These last two are the real deal for a busting MAB, as in Leronlimab:
1. Leronlimab attacks 2 new things, a) Tumor-promoting inflammation and b) Avoiding immune destruction.
2. CCR5 blockade with Leronlimab reduces inflammation and keeps the immune system fully charged so that tumor cells don't fool the army, navy, air force or marines. Nothing gets by the militia when Leronlimab is on board. But, Leronlimab does all its work in stealth. It does not explode bombs to make itself known. It kills its target by suffocation.
A few more for Monday morning - regarding our favorite Mab for Leronlimab:
7. The strongest binding affinity to CCR5 is Leronlimab. Therefore, Leronlimab has MINIMAL competition. Too many other drugs have side effects.
8. 700 mg Leronlimab in Combination with Carboplatin is WELL tolerated and that combination trial currently IS being PLANNED.
Here's 4, 5, 6:
1. Leronlimab reduces cancer metastasis and reduces the tumor.
2. Leronlimab prevents the development of blood supply to the tumor.
3. Leronlimab encourages the army, recruits the Navy, enlists the air force and marines into an anti-inflammatory war against the tumor which is passive in nature. It starves the tumor, it suffocates the tumor, it extinguishes the tumor and prevents it from spreading. No inflammation.
I think someone is twisting my arm. Here is number 3:
these statements are supported by data. In layman's terms, Leronlimab turns the soldiers that suppress the army into soldiers that attack the cancer.
Here the researcher, specialist, physician reiterates:
And finally, the CCL5 suppresses also cytotoxic T-Cells that I mentioned, hence, promotes the growth of Tregs regulatory cells and TH responses, which means it suppresses the immune system. And there you go with leronlimab binding to the CCR5 across this breast cancer cell and cell lines and up to almost, not quite, 100% efficiency.
I am not making up this beautiful language. I am copying verbatim the DATA!
Just in case there are new investors who are trying to decipher exactly what Leronlimab does, here is a punch list with ten separate items. I'll post the first two now and then over the next day continue to add to the list.
1. Some soldiers of the white blood cell army improperly function. Instead of attacking cancer, they actually suppress the army, thereby allowing the cancer to live.
2. The objective is to get the immune system to work again. And it is accomplished by clearing the obstacles out of the way so the immune system can do its job.
Simple description but the human body is very complex. Stay tuned.
JohnCM: Have not heard from you in a loooong time! Glad you're back and buying CWEB.
Tell that to our buddy who has 6 gears in his car...
How about shorting? Do you think nobody is shorting this stock? If you disagree, you don't know anything about the current stock market. Shorter's delight.
The way the three in the cab described - a diesel truck has a ton of gears that one has to shift up and down. The electric truck by Nikola has a forward and backward gear. How's that?
Very quiet and only one gear!
MOST MJ stocks down today.
Whatever WISE WQLF!
If I may reiterate the current environment of all cannabis stocks. They are down, significantly.
Last year at this time, Trulieve was $26 - now about $5.
Curaleaf, Tilray - you name it. Jushi was $6, now $.46!
Charlotte's Web was about $1.42 now $.30 cents. Charlotte's Web is doing better than
Jushi.
Cresco was $9 now $1.66!
Plenty of names to buy out but I doubt any will be sold. Compression and shorting are upon us until the FEDS declassify and Congress passes the Safe Banking Act.
Just a year ago this stock was in the dollar range....
I think they all know that now...
The struggling fledgling company always has problems. It has to get diluted. If you listen to the CEO's last interview, he says pretty much the same. That's why they had to sell the European market.
Okay so I watched it and Whoa....
The ACT convention of BVEV and FCEV big rigs and trucks was last week. Anyway....
Nikola has built both types of trucks but the FCEV gets 500 miles to the tank and takes 20 minutes to refuel while the EV gets 300 miles to the tank and take 90 minutes to refuel....
Also some analysts are making a big deal that Nikola pulled out of the European market and concentrating solely on the North American market. Nikola sold their business to Iveco, their competitor in Europe but.... but... they have signed a strategic deal with Iveco for parts and other things.
Smart to concentrate on North America where no one else is right now. First mover advantage. I am buying more shares this morning...
Anyone look at the Nikola, youtube video last night? The ACT convention of BVEV and FCEV big rigs and trucks was last week. Anyway....
Nikola has built both types of trucks but the FCEV gets 500 miles to the tank and takes 20 minutes to refuel while the EV gets 300 miles to the tank and take 90 minutes to refuel....
Fumbler: You do realize that this article was published 16 months ago on January 10, 2022! Like really old news in the world of biotech!
How many votes do they need to pass #5?
I'm in - all in with a YES vote for #5.
By the way, this is not an A.I. generated video. Melon Toy is real. The name is unusual but she is a Covid victim.
Plug is down $1.28. Crazy…
We won't know, for certain, if the shareholders vote was negative but if Blackrock indeed owns 41 millions acres, surely they will vote positive?...
I’m rooting for you - $2.50!
Look Hoghead all I care about is the very immediate future - like today. Will we hit your sp goal of $2.50. Off to a good start...before the bell...
Hansen is part of the new triumvirate in biotech! And a major part of VIR Technology. VIR is an amazing company at the forefront of a new paradigm in medicine.
This is from LinkedIn:
"I received my Ph.D. in Microbiology from Oregon State University in 2001 under the mentorship of Dr. Dennis Hruby. After completing my degree, I took a post-doctoral position in the laboratory of Dr. Jay Nelson at OHSU’s Vaccine and Gene Therapy Institute, located on the campus of the Oregon National Primate Research Center. Working with Dr. Nelson and Dr. Louis Picker, I studied the Rhesus Cytomegalovirus (RhCMV) rhesus macaque model (RM) of infection, recombination, and immunobiology.
Currently I'm an Assistant Scientist working with Dr. Picker. Together we have pioneered the idea of “effector memory” -biased T cell (TEM) vaccines. Specifically, our research has focused on the development of recombinant CMV vectors, which generate and maintain TEM responses. Using the RhCMV and RM model we have demonstrated that RhCMV/SIV vectors can super-infect RhCMV+ RM, and upon super-infection elicit potent, persistent, and broadly targeted SIV-specific CD4+ and CD8+ T cell responses with a strong TEM bias. In the prophylactic vaccine setting, these responses have completely protected ~50% of vaccinated RM from progressive infection after limiting dose rectal challenge with the highly pathogenic SIVmac239 virus. These data indicate a novel pattern of protection consistent with very early stringent control, followed by progressive clearance of residual viral reservoirs, likely CD8+ TEM-mediated.
My current research is focused on designing and testing CMV vectors with genetically engineered restrictions in replication and dissemination/spread, with the goal to developing the safest CMV vectors with the greatest immunogenicity and protective capacity."
Picker, Hansen, Sacha - go to PubMed and look up their names.... They are together many times publishing....
Settle down now.
One last thing: "I can't wait for the first shared patent!"
Hansen's lab and the MAB - leronlimab!
IT CAN'T BE TRUE! Check out the bio on Dr. Scott Hansen:
Dr. Hansen’s research laboratory has been studying leronlimab since the Spring of 2021. In this time he has developed numerous flow cytometry biomarker assays to investigate how leronlimab/CCR5 modulates various immune cell phenotypes. Additionally, he developed an exploratory CCR5 receptor occupancy assay to evaluate leronlimab binding/loading after dosing. Dr. Hansen’s work has led to two research publications (one pending publication) that has already furthered CytoDyn’s understanding on the mechanism of action and potential applications of leronlimab in NASH and oncology.
SINCE 2021!!!
Oh No. It can't be true.
Check this out - a new member to CYDY's team - SCOTT HANSEN!
Can I say, "I'm cuckoo for cocoa Hansen's!"
https://www.cytodyn.com/our-team/management-team
scroll down
Even though this is about PLUG, FCEL could sooooooo easily do this too....
https://www.yahoo.com/finance/m/bf034fea-14a5-3162-aaa8-78347fd993a3/hydrogen-player-plug-power.html
Or maybe the fusion of Columbia Care into Cresco
Toyota hydrogen -conversion kit..
https://www.yahoo.com/autos/toyota-hydrogen-semi-conversion-kit-123900075.html
I think you are mistakenly using lol
Yes, I'm crazy. Just bought more. The price is just silly now with all its future prospects...nailed down.
I know that this is insane to say on this board but buying more of CYDY!